Haleos Labs Limited Upgraded to Sell on Technical Improvement Despite Weak Financials

Quality Assessment: Weak Fundamentals Persist

Haleos Labs Limited continues to exhibit weak long-term fundamental strength, which remains a significant concern for investors. The company’s average Return on Capital Employed (ROCE) stands at a modest 8.38%, indicating limited efficiency in generating profits from its capital base. Over the past five years, net sales have grown at a sluggish annual rate of just 2.46%, while operating profit growth has been even more restrained at 1.47% per annum. These figures underscore the company’s struggle to achieve meaningful top-line and bottom-line expansion in a competitive Pharmaceuticals & Biotechnology sector.

Moreover, the company’s ability to service debt is under pressure, with a high Debt to EBITDA ratio of 2.54 times. This elevated leverage ratio raises concerns about financial risk, especially given the recent negative quarterly results. In Q1 FY26-27, Haleos Labs reported a sharp decline in net sales by 11.59%, with Profit Before Tax (PBT) excluding other income falling by 50.50% to ₹2.98 crores and Profit After Tax (PAT) dropping 36.3% to ₹2.65 crores. These consecutive quarters of negative earnings highlight ongoing operational challenges.

Valuation: Attractive but Reflective of Risks

Despite the weak financial performance, the valuation of Haleos Labs remains relatively attractive. The company’s ROCE of 8.7% pairs with an Enterprise Value to Capital Employed ratio of 1.7, suggesting that the stock is trading at a discount compared to its peers’ historical averages. This valuation discount may appeal to value-oriented investors willing to tolerate near-term volatility for potential long-term gains.

However, it is important to note that while the stock price has generated a robust return of 24.85% over the last year, this has come amid a decline in profits by approximately 8.5%. This divergence between price appreciation and earnings contraction signals a disconnect that investors should carefully consider when evaluating the stock’s risk-reward profile.

Financial Trend: Recent Results Marked by Negative Performance

The financial trend for Haleos Labs remains decidedly negative in the short term. The company has reported negative results for two consecutive quarters, including the quarter ended June 2026. Net sales for this period were the lowest in recent history at ₹72.94 crores, reflecting a contraction in business activity. The sharp declines in PBT and PAT further emphasise the deteriorating profitability.

These results contrast with the company’s longer-term market performance, where it has outperformed the BSE500 index significantly. Over the past three years, Haleos Labs has delivered a cumulative return of 190.92%, compared to the BSE500’s 13.36%. Similarly, the one-year return of 24.85% far exceeds the index’s negative 8.86% return. This market-beating performance suggests that investors have priced in expectations of recovery or other favourable factors despite the recent financial setbacks.

Technical Analysis: Mildly Bullish Signals Drive Upgrade

The primary catalyst for the upgrade from Strong Sell to Sell is the improvement in technical indicators. The technical trend has shifted from sideways to mildly bullish, signalling a potential stabilisation or modest upward momentum in the stock price. Daily moving averages have turned mildly bullish, supporting this positive shift.

However, the technical picture remains mixed. Weekly MACD is mildly bearish, while monthly MACD is bullish, indicating some divergence in momentum across timeframes. The Relative Strength Index (RSI) on both weekly and monthly charts shows no clear signal, suggesting a neutral momentum stance. Bollinger Bands present a mildly bearish outlook on the weekly chart but mildly bullish on the monthly chart, further highlighting the nuanced technical environment.

Other indicators such as the KST (Know Sure Thing) and Dow Theory remain mildly bearish on the weekly scale, with no clear trend on the monthly scale. On-Balance Volume (OBV) shows no trend weekly and mildly bearish monthly, indicating subdued volume support for price moves. Overall, these mixed signals justify a cautious upgrade, reflecting a tentative improvement rather than a strong bullish conviction.

Stock Price and Market Capitalisation Context

Haleos Labs is classified as a micro-cap stock, with a current price of ₹1,498.25 as of 24 September 2026, down 2.27% from the previous close of ₹1,533.00. The stock’s 52-week high stands at ₹1,778.35, while the 52-week low is ₹1,100.60, indicating a relatively wide trading range. Today’s intraday high and low were ₹1,552.35 and ₹1,489.00 respectively, reflecting some volatility.

Despite the recent price dip, the stock has outperformed the Sensex across multiple time horizons. Over one week, Haleos Labs returned 1.69% versus Sensex’s 0.66%. Over one month, the stock gained 2.54% while the Sensex declined 3.50%. Year-to-date, the stock is up 17.51% compared to the Sensex’s negative 12.19%. These figures highlight the stock’s resilience amid broader market weakness.

Shareholding and Sector Positioning

The majority shareholders of Haleos Labs remain the promoters, maintaining significant control over the company’s strategic direction. Operating within the Pharmaceuticals & Biotechnology sector, Haleos Labs faces intense competition and regulatory challenges that impact its growth trajectory and profitability.

Its micro-cap status places it in a category often characterised by higher volatility and risk, which is reflected in the mixed technical and fundamental signals observed. Investors should weigh these factors carefully when considering exposure to this stock.

Conclusion: A Cautious Upgrade Reflecting Technical Optimism Amid Fundamental Weakness

The upgrade of Haleos Labs Limited’s investment rating from Strong Sell to Sell is primarily driven by a mild improvement in technical indicators, signalling a tentative shift towards bullish momentum. However, this positive technical development is tempered by persistent fundamental weaknesses, including poor financial performance, low growth rates, and high leverage.

Valuation metrics suggest the stock is attractively priced relative to peers, but the disconnect between rising stock returns and declining profits warrants caution. The company’s recent negative quarterly results further highlight operational challenges that may constrain near-term recovery.

Overall, the rating change reflects a nuanced view: while technical signals offer some optimism, fundamental concerns remain significant. Investors should monitor upcoming quarterly results and sector developments closely before increasing exposure to Haleos Labs.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →